Press Releases
Date picker
Category
Results per page
Kancera initiates process to seek stakeholders for a reverse take over
Regulatory
Kancera AB (publ) (“Kancera”) today announces that the board has decided to initiate a process to seek potential stakeholders for a reverse take over of the company with the aim…
Interim Report First Quarter 2025, April 1 – June 30 Kancera AB (publ.), org.no. 556806-8851
Regulatory
The period in brief – financial summary for the second quarter 2025Net sales amounted to SEK 0 million (SEK 0 million).R&D expenses amounted to SEK 4,8 million (SEK 9,7 million).Operating…
Kancera terminates letter of intent with Recardio
Regulatory
Kancera AB (publ) today announces that the company has terminated the letter of intent agreement with Recardio Inc. based on financing considerations. Kancera will now explore other out-licensing and business…
Kancera announces rugocrixan and fosrugocrixan as the International Non-proprietary Names for KAND567 and KAN145
Kancera AB (publ) (Kancera) announces that the World Health Organization has granted rugocrixan and fosrugocrixan as the International Non-proprietary Names for the company’s candidate drugs KAND567 and KAND145.
Kancera reports positive top-line results from the KANDOVA study
Regulatory
Kancera AB (publ) (Kancera) today reports the top-line results from the KANDOVA study, a one-arm, open-label, multi-centre combined phase Ib/IIa study of KAND567 in combination with carboplatin in ovarian cancer.The…
Kancera reports positive outcome of pre-IND meeting with FDA
Regulatory
Kancera AB (publ) (Kancera) today reports that it has completed a successful pre-IND meeting with the FDA and received positive feedback on the planned clinical development program for KAND567 in…
Interim Report First Quarter 2025, January 1 – March 31 Kancera AB (publ.), org.no. 556806-8851
Regulatory
The period in brief – financial summary for the first quarter 2025Net sales amounted to SEK 0 million (SEK 0 million).R&D expenses amounted to SEK 11,1 million (SEK 11,4 million).Operating…
Kancera provides an update on the collaboration with Recardio Inc. and the company’s clinical development program
In connection with the upcoming financial interim report for the first quarter 2025, Kancera AB (publ) (Kancera) provides an update on the ongoing collaboration with Recardio Inc. and the company’s…
Kancera reports Last Patient Last Visit in the KANDOVA study
Kancera AB (publ) reports that the last patient has completed the last visit in the ongoing phase Ib/IIa study KANDOVA evaluating the candidate drug KAND567 in ovarian cancer.
Kancera changes Certified Adviser to Redeye AB
Regulatory
Kancera AB (publ) has entered into an agreement with Redeye AB regarding the service as Certified Adviser. Redeye AB will take over as Certified Adviser on April 1, 2025.